Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P31930
UPID:
QCR1_HUMAN
Alternative names:
Complex III subunit 1; Core protein I; Ubiquinol-cytochrome-c reductase complex core protein 1
Alternative UPACC:
P31930; B2R7R8; Q96DD2
Background:
Cytochrome b-c1 complex subunit 1, mitochondrial, also known as Complex III subunit 1, plays a pivotal role in the mitochondrial electron transport chain. This protein is integral to oxidative phosphorylation, facilitating the transfer of electrons from ubiquinol to cytochrome c, and contributing to the creation of an electrochemical gradient essential for ATP synthesis.
Therapeutic significance:
Given its involvement in Parkinsonism with polyneuropathy, a disorder characterized by late-onset parkinsonism and sensorimotor polyneuropathy, understanding the role of Cytochrome b-c1 complex subunit 1 could open doors to potential therapeutic strategies.